Skip to content 
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs using a platform that permits precise characterization of protein interactions in living cells. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California. more
| Dec '23 | Dec '24 | |||||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Cost of Revenue | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Gross Profit | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Gross Margin | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Operating Expenses | 265.74M | 260.34M | [{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":97.97,"profit":true}] | |||
| Operating Income | (265.74M) | (260.34M) | [{"date":"2023-12-31","value":-26573700000,"profit":false},{"date":"2024-12-31","value":-26034300000,"profit":false}] | |||
| Total Non-Operating Income/Expense | 23.74M | 16.53M | [{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":69.63,"profit":true}] | |||
| Pre-Tax Income | (242.00M) | (243.81M) | [{"date":"2023-12-31","value":-24199700000,"profit":false},{"date":"2024-12-31","value":-24381400000,"profit":false}] | |||
| Income Taxes | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Income After Taxes | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Income From Continuous Operations | (242.00M) | (243.81M) | [{"date":"2023-12-31","value":-24199700000,"profit":false},{"date":"2024-12-31","value":-24381400000,"profit":false}] | |||
| Income From Discontinued Operations | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
| Net Income | (242.00M) | (243.81M) | [{"date":"2023-12-31","value":-24199700000,"profit":false},{"date":"2024-12-31","value":-24381400000,"profit":false}] | |||
| EPS (Diluted) | - | - | [{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] | |||
These ratios help you determine the liquidity of the company. Higher is better.
| EIKN | |
|---|---|
| Current Ratio | 8.69 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| EIKN | |
|---|---|
| ROA (LTM) | 0.00% |
| ROE (LTM) | 0.00% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| EIKN | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 2.24 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -1.24 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| EIKN | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.00 |
| EV/R | 0.00 |
| EV/Ebitda | NM |
Eikon Therapeutics, Inc. Common Stock (EIKN) share price today is $16.26
Yes, Indians can buy shares of Eikon Therapeutics, Inc. Common Stock (EIKN) on Vested. To buy
Yes, you can purchase fractional shares of Eikon Therapeutics, Inc. Common Stock (EIKN) via the Vested app. You can start investing in Eikon Therapeutics, Inc. Common Stock (EIKN) with a minimum investment of $1.
You can invest in shares of Eikon Therapeutics, Inc. Common Stock (EIKN) via Vested in three simple steps:
The 52-week high price of Eikon Therapeutics, Inc. Common Stock (EIKN) is $17.4. The 52-week low price of Eikon Therapeutics, Inc. Common Stock (EIKN) is $13.29.
The price-to-earnings (P/E) ratio of Eikon Therapeutics, Inc. Common Stock (EIKN) is
The price-to-book (P/B) ratio of Eikon Therapeutics, Inc. Common Stock (EIKN) is 0.00
The dividend yield of Eikon Therapeutics, Inc. Common Stock (EIKN) is 0.00%
The market capitalization of Eikon Therapeutics, Inc. Common Stock (EIKN) is $848.63M
The stock symbol (or ticker) of Eikon Therapeutics, Inc. Common Stock is EIKN
Consider the share price of Eikon Therapeutics, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Eikon Therapeutics, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Eikon Therapeutics, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Eikon Therapeutics, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Eikon Therapeutics, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Eikon Therapeutics, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
